Coughlin Stoia Attys Seek $18M In Celexa Deal Fees

Law360, New York (February 2, 2009, 12:00 AM EST) -- Lead counsel for the plaintiffs in a securities class action alleging that Forest Laboratories Inc. provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro have asked for more than $18 million in fees and expenses.

In a motion filed Friday in the U.S. District Court for the Southern District of New York, lead plaintiffs' counsel Coughlin Stoia Geller Rudman & Robbins LLP asked for 24.5 percent of the proposed $65 million settlement fund and about $1.4 million in expenses plus interest....
To view the full article, register now.